However, various shortcomings of insulin therapies, such as the injectable nature of insulin, the development of insulin resistance, and the inability to reach excellent glycemic control due to hyperglycemia and hypoglycemia, have motivated researchers to develop noninsulin pharmacological therapies to manage T1DM. This evidence concerns the gene INS and type 1 diabetes mellitus.